Biomarkers for neurodegenerative diseases
O Hansson - Nature medicine, 2021 - nature.com
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
Blood biomarkers for Alzheimer's disease in clinical practice and trials
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
2018 Alzheimer's disease facts and figures
Alzheimer's Association - Alzheimer's & Dementia, 2018 - Elsevier
This article describes the public health impact of Alzheimer's disease (AD), including
incidence and prevalence, mortality and morbidity, costs of care, and the overall impact on …
incidence and prevalence, mortality and morbidity, costs of care, and the overall impact on …
2016 Alzheimer's disease facts and figures
Alzheimer's Association - Alzheimer's & Dementia, 2016 - Elsevier
This report describes the public health impact of Alzheimer's disease, including incidence
and prevalence, mortality rates, costs of care, and the overall impact on caregivers and …
and prevalence, mortality rates, costs of care, and the overall impact on caregivers and …
Systematic review of miRNA as biomarkers in Alzheimer's disease
Currently there are 850,000 people with Alzheimer's disease in the UK, with an estimated
rise to 1.1 million by 2025. Alzheimer's disease is characterised by the accumulation of …
rise to 1.1 million by 2025. Alzheimer's disease is characterised by the accumulation of …
Mild cognitive impairment
AM Sanford - Clinics in geriatric medicine, 2017 - geriatric.theclinics.com
Mild cognitive impairment (MCI), first fully characterized by Petersen and associates in 1997,
1 generally refers to impairment in cognition above that which is seen with normal age …
1 generally refers to impairment in cognition above that which is seen with normal age …
2017 Alzheimer's disease facts and figures
Alzheimer's Association - Alzheimer's & Dementia, 2017 - Elsevier
This article describes the public health impact of Alzheimer's disease (AD), including
incidence and prevalence, mortality rates, costs of care, and the overall impact on caregivers …
incidence and prevalence, mortality rates, costs of care, and the overall impact on caregivers …
2015 Alzheimer's disease facts and figures
Alzheimer's Association - Alzheimer's & Dementia, 2015 - Wiley Online Library
This report discusses the public health impact of Alzheimer's disease (AD), including
incidence and prevalence, mortality rates, costs of care and the overall effect on caregivers …
incidence and prevalence, mortality rates, costs of care and the overall effect on caregivers …
Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis
JL Liss, S Seleri Assunção, J Cummings… - Journal of internal …, 2021 - Wiley Online Library
The critical role of primary care clinicians (PCCs) in Alzheimer's disease (AD) prevention,
diagnosis and management must evolve as new treatment paradigms and disease …
diagnosis and management must evolve as new treatment paradigms and disease …